ICIP is under clinical development by Chosa Oncology and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ICIP’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
iCIP is under development for the treatment of advance and refractory tumors including metastatic breast cancer and Non-small cell lung cancer. The drug candidate is accompanied by a LiPlaCis and companion diagnostic test DRP. The drug candidate is administered through intravenous route. Cisplatin is an inorganic platinum agent (cis-diamminedichloroplatinum) which targets DNA and elicits anti-neoplastic activity. The drug candidate is developed using Liposomal technology.
Chosa Oncology overview
Chosa Oncology, formerly RhoVac, is a biotechnology company. It focuses on research and development of immunotherapeutic drugs. The company develops therapeutic cancer vaccines to prevent or limit metastasis in metastatic cancers. Its key products include LiPlaCis and DRP, which are under the clinical phase II process. LiPlaCis is a liposomal formulation of the chemotherapy drug cisplatin, which enables direct delivery of a known agent to tumor sites. DRP is a multigene mRNA-based Drug-specific Response Predictor that is developed upon a deep systems biology analysis of transcriptional (RNA) changes in tumor cells. The company operates in Denmark and Sweden. Chosa Oncology is headquartered in Lund, Sweden.
For a complete picture of ICIP’s drug-specific PTSR and LoA scores, buy the report here.